SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

Other languages Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Equities

600196

CNE000000X38

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
22.73 ^CNY	-0.09%		-0.22%	-9.19%

Apr. 24	Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator	MT
Apr. 18	China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator	Apr. 24
China Accepts New Drug Applications for Fosun Pharma's Iron Overload Syndrome Drugs	Apr. 08
Fosun Pharma's 2023 Attributable Profit Declines, Misses Estimates	Mar. 26
Shanghai Fosun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	Mar. 26
Shanghai Fosun Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023	Mar. 26
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26
Shanghai Fosun Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	Mar. 25
Shanghai Fosun Pharma Unit's Oral Schizophrenia Drug Gets Marketing Registration	Mar. 14
Fosun Pharma Unit Gets China OK for Phase I Trial for Solid Tumor Drug	Mar. 08
Fosun Pharma Unit to Start First Phase of Trial of Cancer Drug Candidate	Mar. 07
Fosun Pharma Chairman Proposes Buyback of Up to 200 Million Yuan	Mar. 04
Fosun Pharma Subsidiaries Get Nod to Trial Leukemia Drugs	Feb. 29
Registration Application of Hypokalemia Drug by Shanghai Fosun Pharmaceutical Unit Accepted by Chinese Regulator	Feb. 20
Yuyuan Tourist Mart CFO Steps Down	Feb. 05
Shanghai Fosun Unit Gets Clearance For China Phase II Trial of Amyloidosis Drug	Jan. 25
China Grants Clinical Trial Approval for Fosun Pharma Unit's Bronchiectasis Tablets	Jan. 15
Fosun Pharma Board Approves Unlocking, Vesting of Shares	Jan. 10
Shanghai Fosun Pharmaceutical Co., Ltd. Enter into Mutual Supply Framework Agreement with Fosun International Limited	Dec. 15
Chinese Drug Regulator Accepts Fosun Pharma Subsidiary's Application for Diet Supplement	Dec. 11
Fosun Pharmaceutical's Unit Scraps Clinical Trial on ORIN1001 Tablet	Dec. 11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Equities

600196

CNE000000X38

Other languages

Filters